Table 1.
IF and antibody profiles in patients suffering from PVeg
| Reference | n | Diagnosis | Sex/age | Involvement |
IF | Autoantibodies |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| skin | mucosa | DSG1 | DSG3 | DSC1 | DSC2 | DSC3 | Other | ||||||
| This report | 1 | PVeg | m/64 | + | − | DIF: IC IgG, IgA, C3; −IgM IIF: IC IgG (ME); − (MB, RB) | − (ELISA) | + (ELISA) | − IgG (IIFHEK) − IgA (IIFHEK) | − IgG (IIFHEK) − IgA (IIFHEK) | − IgG (IIFHEK) − IgA (IIFHEK) | ||
| Kockritz et al., 2017 [34] | 1 | PVeg | f/76 | + | + | DIF: IC IgG, C3 IIF: IC (IgG) (ME) | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| Akkari et al., 2015 [33] | 1 | PVeg | f/47 | + | + | DIF: IC IgG IIF: nr | nr | + (nr) | nr | nr | nr | ||
| Mori et al., 2015 [8] | 1 | PVeg | m/42 | + | − | DIF: IC IgG IIF: + (ME) | nr | + (ELISA) | nr | nr | nr | ||
| Salah, 2015 [32] | 1 | PVeg | f/72 | + | − | DIF: nr IIF: nr | nr | + (ELISA) | nr | nr | nr | ||
| Mendes-Bastos et al., 2015 [9] | 1 | PVeg | f/45 | + | + | DIF: IC IgG | + (ELISA) | + (ELISA) | nr | nr | nr | ||
| Hatano et al., 2014 [31] | 1 | BPveg/ PVeg | m/85 | + | − | DIF: BMZ IgG, C3; − IgA, IgM IIF: BMZ IgG; − IgA (HS, ME) IFbio: IC (ME) | + (ELISA) + (IFbio) | − (ELISA) + (IFbio) | − IgG (ELISA) − IgA (ELISA) | − IgG (ELISA) − IgA (ELISA) | − IgG (ELISA) − IgA (ELISA) | BP230: + (ELISA); − (IFbio) BP180: − (ELISA); − (IFbio) laminin 332: − (IB) BP180 NC 16a: − (IB) C-terminal domain of BP180: − (IB) HEE: − (IB) HDE: − (IB) | |
| Saruta et al., 2013 [3] | 2 | PVeg | f/80s | + | nr | DIF: IC C3; − IgG, IgM, IgA IIF: IC IgG; − IgA (ME); − IgG, IgA (HS) | + (ELISA) | − (ELISA) | − IgG (IB) − IgA (IB) − IgG (ELISA) | − IgG (IB) − IgA (IB) − IgG (ELISA) | + IgG (IB) − IgA (IB) + IgG (ELISA) | HEE: IgG 100, 110, 160 kDa (IB) | |
| f/70s | + | nr | DIF: − C3, IgG, IgM, IgA IIF: IC IgG; − IgA (ME); − IgA, IgG (HS) | − (ELISA) | − (ELISA) | − IgG (ELISA) nr IgA | + IgG (ELISA) nr IgA | + IgG (IB) (ELISA) nr IgA | HEE: IgG 100, 110, (ELISA) nr IgA | ||||
| Apalla et al., 2013 [10] | 1 | PVeg | f/68 | − | + | DIF: IC IgG 2013 [10] | nr | + (ELISA) | nr | nr | nr | ||
| Wolz et al., 2013 [11] | 2 | PVeg | m/21 | + | + | DIF: IC IgA IIF: IC IgA (ME) | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| m/58 | + | + | DIF: IC IgA, IgG BMZ IgG, C3 IIF: IC IgA (ME); BMZ IgG (HS); − (RB) | − (nr) | − (nr) | nr | nr | nr | BP230: + (ELISA) BP180: − (nr) | ||||
| Rafei et al., 2011 [5] | 2 | PVeg | nr nr | + + | + - | DIF: IC IgG IIF: IC IgG (ME) DIF: IC IgG IIF: IC IgG (ME, HS, CHK) | − (IB) + (IB) | − (IB) − (IB) | − IgG (IB) − IgG (IB) | − IgG (IB) − IgG (IB) | + IgG (IB) + IgG (IB) | ||
| Son et al., 2011 [12] | 1 | PVeg | f/63 | + | + | DIF: nr IIF: nr | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| Wei et al., 2011 [13] | 1 | PVeg | m/72 | + | − | DIF: IC IgG, C3 IIF: IC IgG (GPE) | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| Zaraa et al., 2011 [2]1 | 17 | PVeg | f (14) m (3) 47.6±13.4 | + (17) | + (15) −(2) | DIF: IC IgG (n = 17/17) IC IGA (n = 2/17) IC IgM (n = 1/17) IC C3 (n = 14/17) IC C1q (n = 2/17) BMZ C3 (n = 1/17) IIF: nr | + (2/8; ELISA) | + (8/8; ELISA) | nr | nr | nr | ||
| Monshi et al., 2010 [14] | 1 | PVeg | f/81 | + | + | DIF: IC IgG, IgG1, IgG4, C3; − IgG2, IgG3 IIF: IC IgG, IgG1, IgG4; − IgA, IgG2, IgG3 (nr) | − (IB, IP) | + (ELISA) | nr | nr | nr | CHKE: − (IB, IP) | |
| Torres et al., 2009 [15] | 1 | PVeg | f/83 | + | nr | DIF: IC IgG, C3 IIF: − (MurB) | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| Adachi et al., 2009 [16] | 1 | PVeg | f/55 | + | + | DIF: IC IgG, C3 IIF: nr | + (ELISA) | + (ELISA) | nr | nr | nr | ||
| Motomura et al., 2009 [17] | 1 | PVeg | f/56 | + | nr | DIF: nr IIF: nr | + (ELISA) | + (ELISA) | nr | nr | nr | ||
| Cozzani et al., 2007 [18] | 2 | PVeg | m/72 | + | + | DIF: IC IgG BMZ C3 IIF: + (ME, RB) | + (ELISA) BMZ C3 IIF: + (ME, RB) | + (ELISA) + (IB) | nr | nr | nr | HEE: 130, 190 kDa (IB) | |
| f/77 | + | + | DIF: IC IgG, C3 BMZ C3 IIF: + (ME, RB) | − (ELISA) − (IB) | + (ELISA) + (IB) | nr | nr | nr | HEE: 130, 190 kDa (IB) | ||||
| Koga et al., 2007 [19] | 1 | PVeg | m/72 | + | + | DIF: IC IgG, C3c, C3d; − IgA, IgM IIF: IC IgG (nr) | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| Kaiser et al., 2007 [20] | 1 | PVeg | f/49 | + | + | DIF: IC IgG IIF: IgG (nr) | nr | + (ELISA) | nr | nr | nr | ||
| Duparc et al., 2006 [21] | 1 | PNP/ PVeg | f/54 | + | + | DIF: IC IgG IIF: IC IgG (RB); − (HS) | − (ELISA) − (IB) | + (ELISA) + (IB) | nr | nr | nr | HEE: 130, 190, 210, 230 kDa (IB) | |
| Danopoulou et al., 2006 [22] | 1 | PVeg | f/54 | + | − | DIF: IC IgG, C3 IIF: nr | − (ELISA) | + (ELISA) | nr | nr | nr | ||
| Morizane et al., 2005 [23] | 1 | PVeg | m/67 | + | + | DIF: IC IgG, IgA, C3 IIF: − IgG, IgA, IgM, C3 (nr) | − IgG, IgA (ELISA) − IgG, IgA (IB) | + IgG, IgA (ELISA) − IgG, IgA (IB) | − IgG (ELISA) − IgG, IgA (IB) | − IgG (ELISA) − IgG, IgA (IB) | − IgG (ELISA) − IgG, IgA (IB) | HEE: − (IB) | |
| Powell et al., 2004 [24] | 1 | PNP/ PVeg | m/69 | + | + | DIF: IC IgG, C3 BMZ IgG, C3 IIF: IC IgG (ME, RB, HS) BMZ IgG (HS) | + (ELISA) − (IB) | + (ELISA) + (IB) | nr | nr | nr | HEE: 130, 170, 190, 210, 250, 190 kDa (IB) | |
| Török et al., 2003 [25] | 1 | PVeg | f/51 | + | + | DIF: IC IgG, C3 IIF: IC IgG (ME, HS) | − (IB) | + (IB) | nr | nr | nr | HEE: 130 kDa (IB) | |
| Sapadin et al., 1998 [26] | 1 | PNP/ | m/54 | + | + | DIF: IC IgG IIF: + (ME, RB) | − (IB) | − (IB) | nr | nr | nr | nr: + 190, 210, 230, 250 kDa (IP) | |
| Ohata et al., 1996 [27] | 1 | PVeg | m/30 | + | + | DIF: IC IgG, C3 IIF: IC IgG (HS) | − (IB) | + (IB) | nr | nr. | nr | HEE: 130 kDa (IB) | |
| Mahé et al., 1994 [28] | 1 | PVeg | m/31 | + | + | DIF: IC IgG BMZ C3 IIF: IC + (HS, RB) | − (IB) | + (IB) | nr | nr | nr | BTE: 130, 190 kDa (IB) | |
| Hashimoto et al., 1994 [4] | 2 | PVeg | f/67 | + | + | DIF: IC IgG IIF: IC IgG (HS) | − (IB) | + (IB) | + IgG (IB) nr IgA | + IgG (IB) nr IgA | nr | HEE: 130 kDa (IB) BDP: 105,115, 135, 150 kDa (IB) | |
| f/33 | + | + | DIF: IC IgG IIF: IC IgG (HS) | − (IB) | + (IB) | + IgG (IB) nr IgA | + IgG (IB) nr IgA | nr | HEE: 130 kDa (IB) BDP: 105, 115, 150 kDa (IB) | ||||
| Hashizume et al., 1993 [29] | 1 | PVeg | f/34 | + | + | DIF: IC IgG, C3 IIF: IC IgG (CHK, GPL) | − (IB) | + (IB) | nr | nr | nr | HEE: 130 kDa (IB) | |
| Parodi et al., 1988 [30] | 1 | PVeg | f/55 | + | + | DIF: IC IgG, C3 IIF: IC IgG (ME) | nr | + (IP) | nr | nr | nr | CHKE: 85, 130 kDa and other not specified chains (IP) | |
Gray shading marks cases where anti-Dsg3 antibodies were detected although mucous membranes were spared. The employed methods of detection are given in parentheses.
BTE, bovine tongue extract; BMZ, basal membrane zone; BPveg, pemphigoid vegetans; CHK, cultured human keratinocytes; CHKE, cultured human keratinocyte extract; DIF, direct immunofluorescence; ELISA, enzyme-linked immunosorbent assay; GPE, guinea-pig esophagus; GPL, guinea-pig lip; HDE, human dermal extract; HEE, human epidermal extract; HS, human skin; IB, immunoblotting; IC, intercellular; IF, immunofluorescence; IIF, indirect immunofluorescence; IFbio, immunofluorescence using biochips; IIFHEK, immunofluorescence on HEK293 cells; IP, immunoprecipitation; MB, monkey bladder; ME, monkey esophagus; MurB, murine bladder; nr, not reported; PNP, paraneoplastic pemphigus; PVeg, pemphigus vegetans; RB, rat bladder.
1
Cumulative presentation of data does not allow correlation of findings in individual patients; antibodies that reacted with DSC 1/2 in bovine desmosome preparation; BDP, bovine desmosome preparation.